Methods of treating sickle cell disease with anti-P-selectin antibodies
US9556266B2 · kind B2 · utility
0Cited by
15References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 1, 2013 |
| Grant date | Jan 31, 2017 |
| Priority date | — |
| Expiry date | Feb 1, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention features antibodies, e.g., chimeric and humanized antibodies, that recognize (i.e., bind) P-selectin. The P-selectin antibodies prevent P-selectin from binding to its cognate receptor. The P-selectin antibodies can be used to treat inflammatory and thrombotic conditions, e.g., sickle cell disease, pain crisis associated with sickle cell disease, deep vein thrombosis, asthma, rheumatoid arthritis, psoriasis, and ischemia reperfusion injury in a patient in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.